Gmax Biopharm

Focus: Gmax Biopharm is a monoclonal antibody platform biotech founded in 2017, based in Hangzhou, China, focused on cardiovascular and metabolic disease therapeutics.

Cardiovascular Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Gmax Biopharm

AI assessmentNot Hiring

No open roles listed right now. Follow Gmax Biopharm to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GMA106 Injection

Overweight and Obesity

Phase 1

Clinical Trials (1)

NCT05054530Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106

Phase 1

Help build intelligence for Gmax Biopharm

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage mAb platform with potential to build foundational IP in high-value therapeutic areas (obesity, PAH)
Ground-floor opportunity at a China-based biotech during early clinical expansion with three Phase 1 programs
Monoclonal antibody focus aligns with sustained industry demand and premium valuation potential

Watch Out For

No current open positions and zero disclosed active hiring, suggesting minimal near-term career entry
All pipeline programs remain in Phase 1 with no Phase 2/3 data, meaning 5+ years before clinical validation or near-term exit catalysts
Private company with no disclosed funding, revenue, or financial transparency limits visibility into cash runway and stability

Generated by Claude from Gmax Biopharm's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GMA301 Injection

Pulmonary Arterial Hypertension

Phase 1

Clinical Trials (1)

NCT04505137A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers

Phase 1

Q4W GMA301 IV injections

Pulmonary Arterial Hypertension

Phase 1

Clinical Trials (1)

NCT04503733A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

Phase 1